Renal Disease — Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation
Citation(s)
A Phase I/II Trial to Evaluate the Safety and Tolerability of Ides® (IgG Endopeptidase) to Eliminate Donor Specific HLA Antibodies (DSAs) and Prevent Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients.